WHO WE ARE

We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS.

At ViiV Healthcare we do things differently. From our unique origins to our innovative medicines, we push the boundaries of what people think is possible in HIV treatment and care.

DEAR HIV & AIDS,

FAIR WARNING, WE’RE NOT GOING ANYWHERE. WHATEVER YOU THROW AT US, WE’LL COME BACK STRONGER. MORE DETERMINED TO ADVANCE THE SCIENCE AND THE PARTNERSHIPS THAT COMBAT YOU AND WHAT YOU DO, AND WILL ONE DAY ERADICATE YOU ALTOGETHER.

UNTIL THAT DAY, WE’RE ViiV HEALTHCARE.

HERE UNTIL YOU AREN’T

If you should know one thing about us, know this: we will not rest until we leave no person living with HIV behind. Until the 38 million people living with HIV is down to zero, we will continue searching for new ways to limit the impact of HIV.¹

Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, at ViiV Healthcare we are determined to help end the HIV epidemic. Our one focused goal unites our employees located across the globe, with their expertise in research, manufacturing, policy and more, all guided by our mission to be here until HIV isn’t.

Our current portfolio of HIV treatment and prevention medicines is our first step in fighting back against the disease. This is only the beginning, as our research center in Branford, Connecticut - the world’s only HIV-dedicated facility - is uniquely focused on finding new innovative medicines to help improve the lives of people living with HIV and those who would benefit from PrEP or pre-exposure prophylaxis.

Also searching to find major breakthroughs against HIV is our HIV Cure Center where we have been dedicating resources and expertise to accelerate novel breakthroughs and maximize the chance of finding an HIV cure.

Alongside our novel approach to R&D, improving access to medicines is just as important in delivering results for people living with HIV or those who would benefit from PrEP. At ViiV Healthcare, we are dedicated to expanding access to ensure those who need our medicines can receive them. Collaborations with organizations such as the International AIDS Society (IAS), Clinton Health Access Initiative (CHAI) and the Medicines Patent Pool (MPP) enable our medicines to make the greatest possible impact in countries around the world. As an example, our voluntary license agreements allow generic manufacturers to develop pediatric formulations of our medicines where 99% of children living with HIV live. We are committed to working ever closer with our partners through continued access initiatives.

To accelerate the HIV response, we put significant focus on community initiatives to strengthen local healthcare services for people living with HIV. Through our Positive Action programs, which back more than 300 projects worldwide, our work with local communities aim to deliver long-lasting impacts on groups such as women and children. We’ve also recently launched HIV In View, ‘Being Seen’, “Love in Gravity”, Risk to Reasons and Me in You, You in Me - all of which are focused on reducing stigma and bias from preventative care and provide patients with the tools they need to get the care they deserve. We seek to enhance local expertise and resources that build toward global goals, as well as our own dedicated mission of leaving no person living with HIV behind.

References: